{
  "study_id": "NCT01673867",
  "study_title": "Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer",
  "table_name": "Table 1",
  "table_title": "Baseline Characteristics, Stratification Factors and Prior Therapy of All Randomized Patients.",
  "description": "Baseline demographic and clinical characteristics of patients randomized to receive either Nivolumab or Docetaxel.",
  "footnotes": [
    "*Includes other plus 1 patient American Indian/Alaska Native for nivolumab and 1 patient Native Hawaiian or other Pacific Islander for docetaxel.",
    "†Mutation status (EGFR or KRAS) or ALK translocation status was not determined through centralized testing; it was not mandatory per the protocol, but was reported by the investigator and collected from case report forms.",
    "‡Derived as number of lines of prior therapy received for advanced, metastatic or recurrent disease received. One patient in the nivolumab group had one prior regimen in the neo-adjuvant setting.",
    "§Some patients may have been treated with more than 1 type of therapy.",
    "ALK = anaplastic lymphoma kinase; ECOG = Eastern Cooperative Oncology Group; EGFR = epidermal growth factor receptor; KRAS= Kirsten rat sarcoma viral oncogene homolog; TKI = tyrosine kinase inhibitor."
  ],
  "groups": [
    {
      "name": "Nivolumab",
      "n": 292,
      "type": "intervention"
    },
    {
      "name": "Docetaxel",
      "n": 290,
      "type": "control"
    },
    {
      "name": "Total",
      "n": 582,
      "type": "total"
    }
  ],
  "characteristics": [
    {
      "original_label": "Median age, years (range)",
      "standardized_name": "age",
      "unit": "years",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "numeric_median_iqr",
          "median": 61.0,
          "iqr_min": 37.0,
          "iqr_max": 84.0,
          "raw_string": "61 (37, 84)",
          "notes": "The source table reports range, not IQR."
        },
        {
          "group_name": "Docetaxel",
          "data_type": "numeric_median_iqr",
          "median": 64.0,
          "iqr_min": 21.0,
          "iqr_max": 85.0,
          "raw_string": "64 (21, 85)",
          "notes": "The source table reports range, not IQR."
        },
        {
          "group_name": "Total",
          "data_type": "numeric_median_iqr",
          "median": 62.0,
          "iqr_min": 21.0,
          "iqr_max": 85.0,
          "raw_string": "62 (21, 85)",
          "notes": "The source table reports range, not IQR."
        }
      ]
    },
    {
      "original_label": "Age categorization, n (%)",
      "standardized_name": "age category",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Docetaxel",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "≥75",
      "standardized_name": "age >= 75 years",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "age category",
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "categorical_count_percentage",
          "count": 20.0,
          "percentage": 7.0,
          "raw_string": "20 (7)"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 23.0,
          "percentage": 8.0,
          "raw_string": "23 (8)"
        },
        {
          "group_name": "Total",
          "data_type": "categorical_count_percentage",
          "count": 43.0,
          "percentage": 7.0,
          "raw_string": "43 (7)"
        }
      ]
    },
    {
      "original_label": "Gender, n (%)",
      "standardized_name": "gender",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Docetaxel",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Male",
      "standardized_name": "male sex",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "gender",
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "categorical_count_percentage",
          "count": 151.0,
          "percentage": 52.0,
          "raw_string": "151 (52)"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 168.0,
          "percentage": 58.0,
          "raw_string": "168 (58)"
        },
        {
          "group_name": "Total",
          "data_type": "categorical_count_percentage",
          "count": 319.0,
          "percentage": 55.0,
          "raw_string": "319 (55)"
        }
      ]
    },
    {
      "original_label": "Race, n (%)",
      "standardized_name": "race",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Docetaxel",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "White",
      "standardized_name": "white race",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "race",
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "categorical_count_percentage",
          "count": 267.0,
          "percentage": 91.0,
          "raw_string": "267 (91)"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 266.0,
          "percentage": 92.0,
          "raw_string": "266 (92)"
        },
        {
          "group_name": "Total",
          "data_type": "categorical_count_percentage",
          "count": 533.0,
          "percentage": 92.0,
          "raw_string": "533 (92)"
        }
      ]
    },
    {
      "original_label": "Asian",
      "standardized_name": "asian race",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "race",
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "categorical_count_percentage",
          "count": 9.0,
          "percentage": 3.0,
          "raw_string": "9 (3)"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 8.0,
          "percentage": 3.0,
          "raw_string": "8 (3)"
        },
        {
          "group_name": "Total",
          "data_type": "categorical_count_percentage",
          "count": 17.0,
          "percentage": 3.0,
          "raw_string": "17 (3)"
        }
      ]
    },
    {
      "original_label": "Black/African American",
      "standardized_name": "black or african american race",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "race",
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "categorical_count_percentage",
          "count": 7.0,
          "percentage": 2.0,
          "raw_string": "7 (2)"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 9.0,
          "percentage": 3.0,
          "raw_string": "9 (3)"
        },
        {
          "group_name": "Total",
          "data_type": "categorical_count_percentage",
          "count": 16.0,
          "percentage": 3.0,
          "raw_string": "16 (3)"
        }
      ]
    },
    {
      "original_label": "Other*",
      "standardized_name": "other race",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "race",
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "categorical_count_percentage",
          "count": 9.0,
          "percentage": 3.0,
          "raw_string": "9 (3)"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 7.0,
          "percentage": 2.0,
          "raw_string": "7 (2)"
        },
        {
          "group_name": "Total",
          "data_type": "categorical_count_percentage",
          "count": 16.0,
          "percentage": 3.0,
          "raw_string": "16 (3)"
        }
      ]
    },
    {
      "original_label": "ECOG performance status, n (%)",
      "standardized_name": "ECOG performance status",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Docetaxel",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "0",
      "standardized_name": "ECOG performance status 0",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG performance status",
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "categorical_count_percentage",
          "count": 84.0,
          "percentage": 29.0,
          "raw_string": "84 (29)"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 95.0,
          "percentage": 33.0,
          "raw_string": "95 (33)"
        },
        {
          "group_name": "Total",
          "data_type": "categorical_count_percentage",
          "count": 179.0,
          "percentage": 31.0,
          "raw_string": "179 (31)"
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "ECOG performance status 1",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG performance status",
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "categorical_count_percentage",
          "count": 208.0,
          "percentage": 71.0,
          "raw_string": "208 (71)"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 193.0,
          "percentage": 67.0,
          "raw_string": "193 (67)"
        },
        {
          "group_name": "Total",
          "data_type": "categorical_count_percentage",
          "count": 401.0,
          "percentage": 69.0,
          "raw_string": "401 (69)"
        }
      ]
    },
    {
      "original_label": "Disease stage, n (%)",
      "standardized_name": "disease stage",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Docetaxel",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Stage IIIB",
      "standardized_name": "stage IIIB disease",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "disease stage",
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "categorical_count_percentage",
          "count": 20.0,
          "percentage": 7.0,
          "raw_string": "20 (7)"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 24.0,
          "percentage": 8.0,
          "raw_string": "24 (8)"
        },
        {
          "group_name": "Total",
          "data_type": "categorical_count_percentage",
          "count": 44.0,
          "percentage": 8.0,
          "raw_string": "44 (8)"
        }
      ]
    },
    {
      "original_label": "Stage IV",
      "standardized_name": "stage IV disease",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "disease stage",
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "categorical_count_percentage",
          "count": 272.0,
          "percentage": 93.0,
          "raw_string": "272 (93)"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 266.0,
          "percentage": 92.0,
          "raw_string": "266 (92)"
        },
        {
          "group_name": "Total",
          "data_type": "categorical_count_percentage",
          "count": 538.0,
          "percentage": 92.0,
          "raw_string": "538 (92)"
        }
      ]
    },
    {
      "original_label": "Smoking status, n (%)",
      "standardized_name": "smoking status",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Docetaxel",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Current/former",
      "standardized_name": "current or former smoker",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "smoking status",
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "categorical_count_percentage",
          "count": 231.0,
          "percentage": 79.0,
          "raw_string": "231 (79)"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 227.0,
          "percentage": 78.0,
          "raw_string": "227 (78)"
        },
        {
          "group_name": "Total",
          "data_type": "categorical_count_percentage",
          "count": 458.0,
          "percentage": 79.0,
          "raw_string": "458 (79)"
        }
      ]
    },
    {
      "original_label": "Never",
      "standardized_name": "never smoker",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "smoking status",
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "categorical_count_percentage",
          "count": 58.0,
          "percentage": 20.0,
          "raw_string": "58 (20)"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 60.0,
          "percentage": 21.0,
          "raw_string": "60 (21)"
        },
        {
          "group_name": "Total",
          "data_type": "categorical_count_percentage",
          "count": 118.0,
          "percentage": 20.0,
          "raw_string": "118 (20)"
        }
      ]
    },
    {
      "original_label": "EGFR mutation status, † n (%)",
      "standardized_name": "EGFR mutation status",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Docetaxel",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Positive",
      "standardized_name": "EGFR mutation positive",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "EGFR mutation status",
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "categorical_count_percentage",
          "count": 44.0,
          "percentage": 15.0,
          "raw_string": "44 (15)"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 38.0,
          "percentage": 13.0,
          "raw_string": "38 (13)"
        },
        {
          "group_name": "Total",
          "data_type": "categorical_count_percentage",
          "count": 82.0,
          "percentage": 14.0,
          "raw_string": "82 (14)"
        }
      ]
    },
    {
      "original_label": "ALK translocation status, † n (%)",
      "standardized_name": "ALK translocation status",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Docetaxel",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Positive",
      "standardized_name": "ALK translocation positive",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ALK translocation status",
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "categorical_count_percentage",
          "count": 13.0,
          "percentage": 4.0,
          "raw_string": "13 (4)"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 8.0,
          "percentage": 3.0,
          "raw_string": "8 (3)"
        },
        {
          "group_name": "Total",
          "data_type": "categorical_count_percentage",
          "count": 21.0,
          "percentage": 4.0,
          "raw_string": "21 (4)"
        }
      ]
    },
    {
      "original_label": "KRAS mutation status, † n (%)",
      "standardized_name": "KRAS mutation status",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Docetaxel",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Positive",
      "standardized_name": "KRAS mutation positive",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "KRAS mutation status",
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "categorical_count_percentage",
          "count": 28.0,
          "percentage": 10.0,
          "raw_string": "28 (10)"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 34.0,
          "percentage": 12.0,
          "raw_string": "34 (12)"
        },
        {
          "group_name": "Total",
          "data_type": "categorical_count_percentage",
          "count": 62.0,
          "percentage": 11.0,
          "raw_string": "62 (11)"
        }
      ]
    },
    {
      "original_label": "Prior maintenance, n (%)",
      "standardized_name": "prior maintenance therapy",
      "category": "Prior Therapy",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "categorical_count_percentage",
          "count": 122.0,
          "percentage": 42.0,
          "raw_string": "122 (42)"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 111.0,
          "percentage": 38.0,
          "raw_string": "111 (38)"
        },
        {
          "group_name": "Total",
          "data_type": "categorical_count_percentage",
          "count": 233.0,
          "percentage": 40.0,
          "raw_string": "233 (40)"
        }
      ]
    },
    {
      "original_label": "Number of prior systemic regimens, ‡ n (%)",
      "standardized_name": "number of prior systemic regimens",
      "category": "Prior Therapy",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Docetaxel",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "1 prior systemic regimen",
      "category": "Prior Therapy",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "number of prior systemic regimens",
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "categorical_count_percentage",
          "count": 256.0,
          "percentage": 88.0,
          "raw_string": "256 (88)"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 259.0,
          "percentage": 89.0,
          "raw_string": "259 (89)"
        },
        {
          "group_name": "Total",
          "data_type": "categorical_count_percentage",
          "count": 515.0,
          "percentage": 89.0,
          "raw_string": "515 (89)"
        }
      ]
    },
    {
      "original_label": "2",
      "standardized_name": "2 prior systemic regimens",
      "category": "Prior Therapy",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "number of prior systemic regimens",
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "categorical_count_percentage",
          "count": 35.0,
          "percentage": 12.0,
          "raw_string": "35 (12)"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 31.0,
          "percentage": 11.0,
          "raw_string": "31 (11)"
        },
        {
          "group_name": "Total",
          "data_type": "categorical_count_percentage",
          "count": 66.0,
          "percentage": 11.0,
          "raw_string": "66 (11)"
        }
      ]
    },
    {
      "original_label": "Type of prior systemic therapy,§ n (%)",
      "standardized_name": "type of prior systemic therapy",
      "category": "Prior Therapy",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Docetaxel",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Prior platinum-based therapy",
      "standardized_name": "prior platinum-based therapy",
      "category": "Prior Therapy",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "type of prior systemic therapy",
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "categorical_count_percentage",
          "count": 292.0,
          "percentage": 100.0,
          "raw_string": "292 (100)"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 290.0,
          "percentage": 100.0,
          "raw_string": "290 (100)"
        },
        {
          "group_name": "Total",
          "data_type": "categorical_count_percentage",
          "count": 582.0,
          "percentage": 100.0,
          "raw_string": "582 (100)"
        }
      ]
    },
    {
      "original_label": "ALK inhibitors",
      "standardized_name": "prior ALK inhibitors",
      "category": "Prior Therapy",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "type of prior systemic therapy",
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "raw_string": "1 (<1)",
          "notes": "Percentage reported as <1"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 1.0,
          "raw_string": "2 (1)"
        },
        {
          "group_name": "Total",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 1.0,
          "raw_string": "3 (1)"
        }
      ]
    },
    {
      "original_label": "EGFR-TKI",
      "standardized_name": "prior EGFR-TKI",
      "category": "Prior Therapy",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "type of prior systemic therapy",
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "categorical_count_percentage",
          "count": 29.0,
          "percentage": 10.0,
          "raw_string": "29 (10)"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 24.0,
          "percentage": 8.0,
          "raw_string": "24 (8)"
        },
        {
          "group_name": "Total",
          "data_type": "categorical_count_percentage",
          "count": 53.0,
          "percentage": 9.0,
          "raw_string": "53 (9)"
        }
      ]
    },
    {
      "original_label": "Best response to most recent prior systemic regimen (per investigator), n (%)",
      "standardized_name": "best response to most recent prior systemic regimen",
      "category": "Prior Therapy",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Docetaxel",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Total",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Complete or partial response",
      "standardized_name": "complete or partial response",
      "category": "Prior Therapy",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "best response to most recent prior systemic regimen",
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "categorical_count_percentage",
          "count": 73.0,
          "percentage": 25.0,
          "raw_string": "73 (25)"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 68.0,
          "percentage": 23.0,
          "raw_string": "68 (23)"
        },
        {
          "group_name": "Total",
          "data_type": "categorical_count_percentage",
          "count": 141.0,
          "percentage": 24.0,
          "raw_string": "141 (24)"
        }
      ]
    },
    {
      "original_label": "Stable disease",
      "standardized_name": "stable disease",
      "category": "Prior Therapy",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "best response to most recent prior systemic regimen",
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "categorical_count_percentage",
          "count": 103.0,
          "percentage": 35.0,
          "raw_string": "103 (35)"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 96.0,
          "percentage": 33.0,
          "raw_string": "96 (33)"
        },
        {
          "group_name": "Total",
          "data_type": "categorical_count_percentage",
          "count": 199.0,
          "percentage": 34.0,
          "raw_string": "199 (34)"
        }
      ]
    },
    {
      "original_label": "Progressive disease",
      "standardized_name": "progressive disease",
      "category": "Prior Therapy",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "best response to most recent prior systemic regimen",
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "categorical_count_percentage",
          "count": 111.0,
          "percentage": 38.0,
          "raw_string": "111 (38)"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 116.0,
          "percentage": 40.0,
          "raw_string": "116 (40)"
        },
        {
          "group_name": "Total",
          "data_type": "categorical_count_percentage",
          "count": 227.0,
          "percentage": 39.0,
          "raw_string": "227 (39)"
        }
      ]
    },
    {
      "original_label": "Unknown/not reported",
      "standardized_name": "unknown or not reported",
      "category": "Prior Therapy",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "best response to most recent prior systemic regimen",
      "group_data": [
        {
          "group_name": "Nivolumab",
          "data_type": "categorical_count_percentage",
          "count": 5.0,
          "percentage": 2.0,
          "raw_string": "5 (2)"
        },
        {
          "group_name": "Docetaxel",
          "data_type": "categorical_count_percentage",
          "count": 10.0,
          "percentage": 3.0,
          "raw_string": "10 (3)"
        },
        {
          "group_name": "Total",
          "data_type": "categorical_count_percentage",
          "count": 15.0,
          "percentage": 3.0,
          "raw_string": "15 (3)"
        }
      ]
    }
  ]
}